SIRT2 and Parkinson disease: The former aspect has also been described in Alzheimer’s and Parkinson’s diseases, where SIRT2 is thought to contribute to the pathogenic mechanism underlying deacetylation of the α-tubulin molecule and for which specific SIRT2-targeting therapies are under development (28, –, 31).